Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib adjuvant therapy for resected EGFR-uncommon mutation NSCLC
ChiCTR2300078018Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Disease-free survival. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300078018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078018.